Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Mar 25;332(7543):689-92.
doi: 10.1136/bmj.38764.572569.7C. Epub 2006 Mar 3.

Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study

Affiliations
Randomized Controlled Trial

Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study

Sophia Zackrisson et al. BMJ. .

Abstract

Objective: To evaluate the rate of over-diagnosis of breast cancer 15 years after the end of the Malmö mammographic screening trial.

Design: Follow-up study.

Setting: Malmö, Sweden.

Subjects: 42 283 women aged 45-69 years at randomisation.

Interventions: Screening for breast cancer with mammography or not (controls). Screening was offered at the end of the randomisation design to both groups aged 45-54 at randomisation but not to groups aged 55-69 at randomisation.

Main outcome measures: Rate of over-diagnosis of breast cancer (in situ and invasive), calculated as incidence in the invited and control groups, during period of randomised design (period 1), during period after randomised design ended (period 2), and at end of follow-up.

Results: In women aged 55-69 years at randomisation the relative rates of over-diagnosis of breast cancer (95% confidence intervals) were 1.32 (1.14 to 1.53) for period 1, 0.92 (0.79 to 1.06) for period 2, and 1.10 (0.99 to 1.22) at the end of follow-up.

Conclusion: Conclusions on over-diagnosis of breast cancer in the Malmö mammographic screening trial can be drawn mainly for women aged 55-69 years at randomisation whose control groups were never screened. Fifteen years after the trial ended the rate of over-diagnosis of breast cancer was 10% in this age group.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Schematic overview of periods 1 (unshaded) and 2 from start of Malmö mammographic screening trial to follow-up 15 years after trial ended
Fig 2
Fig 2
Cumulative number of all breast cancer cases (in situ and invasive) per year and group for total follow-up of women born during 1908-22 (unscreened control group) and 1923-32 (controls groups invited to screening from 1990 onwards)

Comment in

References

    1. Baines CJ. Are there downsides to mammography screening? Breast J 2005;11: S7-10. - PubMed
    1. Duffy SW. Some current issues in breast cancer screening. J Med Screen 2005;12: 128-33. - PubMed
    1. Day NE. Overdiagnosis and breast cancer screening. Breast Cancer Res 2005;7: 228-9. - PMC - PubMed
    1. Paci E, Warwick J, Falini P, Duffy SW. Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen 2004;11: 23-7. - PubMed
    1. Olsen AH, Jensen A, Njor SH, Villadsen E, Schwartz W, Vejborg I, et al. Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer 2003;88: 362-5. - PMC - PubMed

Publication types